COMMUNIQUÉS West-GlobeNewswire

Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
19/03/2026
Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K [...]
Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
20/03/2026
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2. Population cible de phase 2 : [...]
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
20/03/2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant [...]
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
20/03/2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
19/03/2026
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally [...]
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
19/03/2026
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash [...]
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
19/03/2026
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Established to Drive [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels pour le Quatrième Trimestre et l'Exercice 2025
19/03/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels pour le Quatrième Trimestre et l'Exercice 2025 La commercialisation aux États-Unis a pris un solide départ au cours du premier trimestre [...]
Curia renforce ses capacités de production à Glasgow et consolide sa plateforme de développement de lignées cellulaires
19/03/2026
ALBANY, New York, 19 mars 2026 (GLOBE NEWSWIRE) -- Curia, acteur majeur de la recherche, du développement et de la fabrication sous contrat (CDMO), annonce ce jour la progression de l’extension de son site de production [...]
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
19/03/2026
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan [...]
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
19/03/2026
Record f ull year 2025 net sales of $ 32.0 , an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
19/03/2026
CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
19/03/2026
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by [...]
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
19/03/2026
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
Glass House Brands to Host Fourth Quarter and Full Year 2025 Earnings Call on March 24, 2026
19/03/2026
LONG BEACH, Calif. and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Trading in GN Store Nord shares by board members, executives and associated persons
19/03/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
19/03/2026
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile [...]
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
19/03/2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic [...]
Solésence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026
19/03/2026
ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]

Pages